Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyBor for GvHD Prevention in Allogeneic HSCT
NCT03945591Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Jun 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and cyclophosphamide in graft-versus-host disease (GVHD), sponsored by NYU Langone Health. Primary endpoints: Percentage of Participants Who Experience Acute GvHD at Day 120 and Percentage of Participants Who Experience Moderate to Severe Chronic GvHD at Day 365. Started Jun 2019; status: completed.
02
Drugs
bortezomibcyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03945591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945591.